Literature DB >> 2548631

The corticotropin-releasing hormone test in patients with posttraumatic stress disorder.

M A Smith1, J Davidson, J C Ritchie, H Kudler, S Lipper, P Chappell, C B Nemeroff.   

Abstract

To evaluate the hypothalamic-pituitary-adrenal (HPA) axis in patients with posttraumatic stress disorder (PTSD), we measured adrenocorticotropin hormone (ACTH) and cortisol responses following administration of corticotropin-releasing hormone (CRH) in 8 combat veterans with chronic PTSD. The PTSD patients had a significantly lower ACTH response to CRH compared to a control group of normal volunteers. Blunted ACTH responses occurred in patients with PTSD alone, as well as those PTSD patients who also had major depression. The cortisol response, although reduced, was not significantly different from normal. The blunted ACTH response to CRH in PTSD patients is similar to that seen in other psychiatric disorders, such as depression, panic disorder, and anorexia nervosa.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2548631     DOI: 10.1016/0006-3223(89)90050-4

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  30 in total

1.  Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder.

Authors:  J D Bremner; J Licinio; A Darnell; J H Krystal; M J Owens; S M Southwick; C B Nemeroff; D S Charney
Journal:  Am J Psychiatry       Date:  1997-05       Impact factor: 18.112

2.  Sex differences in neurosteroid and hormonal responses to metyrapone in posttraumatic stress disorder.

Authors:  Sabra S Inslicht; Anne Richards; Erin Madden; Madhu N Rao; Aoife O'Donovan; Lisa S Talbot; Evelyn Rucker; Thomas J Metzler; Richard L Hauger; Thomas C Neylan
Journal:  Psychopharmacology (Berl)       Date:  2014-06-21       Impact factor: 4.530

3.  Corticotropin-releasing factor receptor 1 antagonist alters regional activation and effective connectivity in an emotional-arousal circuit during expectation of abdominal pain.

Authors:  Catherine S Hubbard; Jennifer S Labus; Joshua Bueller; Jean Stains; Brandall Suyenobu; George E Dukes; Dennis L Kelleher; Kirsten Tillisch; Bruce D Naliboff; Emeran A Mayer
Journal:  J Neurosci       Date:  2011-08-31       Impact factor: 6.167

4.  Alpha-helical CRF blocks differential influence of corticotropin releasing factor (CRF) on appetitive and aversive memory retrieval in rats.

Authors:  K B Kumar; K S Karanth
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

5.  Alterations in stress reactivity after long-term treatment with paroxetine in women with posttraumatic stress disorder.

Authors:  Eric Vermetten; Meena Vythilingam; Christian Schmahl; Carien DE Kloet; Steven M Southwick; Dennis S Charney; J Douglas Bremner
Journal:  Ann N Y Acad Sci       Date:  2006-07       Impact factor: 5.691

Review 6.  Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date.

Authors:  Glenn R Valdez
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 7.  The predator odor avoidance model of post-traumatic stress disorder in rats.

Authors:  Lucas Albrechet-Souza; Nicholas W Gilpin
Journal:  Behav Pharmacol       Date:  2019-04       Impact factor: 2.293

8.  Neuronal mechanisms of increased accessibility of unpleasant memories in helpless rats - a summary of present findings and implication.

Authors:  K B Kumar; K S Karanth
Journal:  Indian J Psychiatry       Date:  1999-07       Impact factor: 1.759

Review 9.  The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology.

Authors:  Elizabeth I Martin; Kerry J Ressler; Elisabeth Binder; Charles B Nemeroff
Journal:  Psychiatr Clin North Am       Date:  2009-09

10.  Adrenocortical responsiveness to infusions of physiological doses of ACTH is not altered in posttraumatic stress disorder.

Authors:  Allen D Radant; Dorcas J Dobie; Elaine R Peskind; M Michele Murburg; Eric C Petrie; Evan D Kanter; Murray A Raskind; Charles W Wilkinson
Journal:  Front Behav Neurosci       Date:  2009-10-30       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.